Andrew Peter O'Brien

BioDiem Ltd. operates as a biotechnology company. It focuses on development and commercialization of pharmaceutical and biomedical research, vaccines and infectious disease therapies and securing licences of biopharmaceutical products currently under development. The firm's development programs include: expansion of the live attenuated influenza virus-based flu vaccine licensing business, development of the antimicrobial BDM-I for the treatment of serious infectious diseases, scrambled antigen vaccine and viral vector systems. The company was founded on May 18, 2001 and is headquartered in South Melbourne, Australia.

Heart Metabolics Ltd. operates as a biopharmaceutical company that engages in developing new treatments for orphan disease including cardio-metabolic diseases. The firm provides drugs to treat heart failure for hypertrophic cardiomyopathy patients. The company was founded by Michael Paul Frenneaux and Houshman Ashrafian in 2004 and is headquartered in Dublin, Ireland.

Snap Network Surveillance Pty Ltd. engages in the provision of video surveillance control software. It offers Snap FMX software that allows customers to take control of large-scale IP video surveillance networks. The company was founded by Anton van den Hengel and Henry Detmold and is headquartered in Adelaide, Australia.

Nexvet Australia Pty Ltd. operates as a global clinical-stage biopharmaceutical company that develops and distributes medicines for companion animals. The firm focuses on transforming the therapeutic market by developing and commercializing novel biologic therapies, including products derived from its PETization technology. PETization is designed to rapidly create monoclonal antibodies that are recognized as “self” by a patient’s immune system. The company was founded by Mark Heffernan, Christopher Nigel Brown and David Gearing in February 2010 and is headquartered in Melbourne, Australia.

Morgan Stanley Australia Ltd. is an Australian broker/dealer subsidiary of Morgan Stanley International, Inc., itself owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in Sydney, the firm offers sales, trading and market-making investment management services to global institutions, hedge funds and industry innovators.